Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma / 中华肝脏病杂志

ABSTRACT

Hepatocellular carcinoma (HCC) is a malignant tumor originating from liver cells. Hepatitis B virus (HBV) infection is the main cause of HCC in 80% of Chinese patients. Pathologically, HCC is usually a kind of tumor with rich blood supply. Transarterial chemoembolization (TACE) can block the blood supply of the tumor, besides, high concentration of chemotherapeutic drugs can be accumulated within the tumor, and therefore TACE can kill tumor cells to the maximum extent. TACE has been recognized as one of the most commonly used non-surgical treatments for HCC. In view of this, after in-depth discussion the expertsfrom Chinese College of Interventionalists, Chinese Medical Doctor Association, put forward,《Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma》. This《Guidelines》contains the following contents about TACE brief introduction of HCC, indications and contraindications, perioperative treatment, euipment and drug preparation, ethical and informed consent, preparation of the patients, procedure,complications and management, evaluation and follow-up, and comprehensive therapy.